Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G4B | P0C869 | 4/20 | 0.65 |
| ▸ | TP53 | P04637 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | RARB | P10826 | 10/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | RARA | P10276 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | MTOR | P42345 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9321559 | 0.98 | PLA2G4B (0.67) | PLA2G4BTP53TSHRRARBMEN1 | |
| SCHEMBL15153312 | 0.98 | PLA2G4B (0.67) | PLA2G4BTP53TSHRRARBMEN1 | |
| SCHEMBL8067972 | 0.95 | RARB (0.65) | PLA2G4BTP53TSHRRARBMEN1 | |
| SCHEMBL1750568 | 0.95 | PLA2G4B (0.63) | PLA2G4BTP53TSHRRARBALDH1A1 | |
| SCHEMBL1749934 | 0.88 | ALDH1A1 (0.57) | PLA2G4BTP53TSHRRARBALDH1A1 | |
| SCHEMBL27945814 | 0.86 | PLA2G4B (0.52) | PLA2G4BTP53TSHRRARBALDH1A1 | |
| SCHEMBL27613996 | 0.86 | NR4A2 (0.59) | PLA2G4BTSHRMEN1ALDH1A1KMT2A | |
| SCHEMBL12354617 | 0.85 | RARB (0.73) | PLA2G4BTP53TSHRRARBMEN1 | |
| SCHEMBL9260821 | 0.85 | RARB (0.64) | PLA2G4BTP53TSHRRARBMEN1 | |
| SCHEMBL9252654 | 0.85 | RARB (0.69) | PLA2G4BTP53TSHRRARBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7968550-B2 | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2011-06-28 | — | — | US | disclosed |
| US-20070207991-A1 | Substituted N-aryl Heterocycles, Process For Their Preparation and Their Use As Medicaments | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-09-06 | — | — | US | disclosed |
| US-7223788-B2 | therapy for eating disorders, anorexigenic agents, antidiabetic agents, reducing weight in mammals, circadian rhythm disease, psychological disorders | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-05-29 | — | — | US | disclosed |
| US-20040220191-A1 | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-11-04 | — | — | US | disclosed |
| EP-1010687-A2 | Ester derivative, liquid crystal composition and liquid crystal display element | Chisso Corporation (JP) | 2000-06-21 | — | — | EP | disclosed |
| US-5755994-A | LARGE DIELECTRIC ANISOTROPIC | CHISSO CORPORATION (JP) | 1998-05-26 | — | — | US | disclosed |
| CN-1136067-A | Liquid crystalline alkynyltolan compound, liquid crystal composition and liquid crystal display element | CHISSO CORP (JP) | 1996-11-20 | — | — | CN | disclosed |
| EP-0738709-A2 | Ester derivate, liquid crystal composition and liquid crystal display element | Chisso Corporation (JP) | 1996-10-23 | — | — | EP | disclosed |
| US-5385693-A | Having rapid response and low phase transition temperature | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1995-01-31 | — | — | US | disclosed |
| EP-0357372-B1 | Optically active ester derivatives, preparation process thereof, liquid crystal materials and a light switching element | SUMITOMO CHEMICAL CO (JP) | 1994-11-17 | — | — | EP | disclosed |
| US-5264151-A | Optically active ester derivatives, preparation process thereof, liquid crystal materials and a light switching element | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1993-11-23 | — | — | US | disclosed |
| US-5124070-A | High speed response | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1992-06-23 | — | — | US | disclosed |
| EP-0357372-A2 | Optically active ester derivatives, preparation process thereof, liquid crystal materials and a light switching element | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1990-03-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220191-A1 | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments | CYP11B2, CYP11B1, CYP1A1 | PLA2G4B 3585/4885TP53 4123/4885TSHR 3707/4885 |
| US-20070207991-A1 | Substituted N-aryl Heterocycles, Process For Their Preparation and Their Use As Medicaments | CYP11B2, CYP11B1, NQO1 | PLA2G4B 3604/4885TP53 4172/4885TSHR 3597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.